'Sinusitis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies Universities.
Sinusitis pipeline therapeutics constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies.
Furthermore, the publisher says; Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
It also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 3, 5 and 2 respectively.
Key Topics Covered:
- Sinusitis Overview
- Therapeutics Development
- Pipeline Products for Sinusitis - Overview
- Pipeline Products for Sinusitis - Comparative Analysis
- Sinusitis - Therapeutics under Development by Companies
- Sinusitis - Therapeutics under Investigation by Universities/Institutes
- Sinusitis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Sinusitis - Products under Development by Companies
- Sinusitis - Products under Investigation by Universities/Institutes
- Sinusitis - Companies Involved in Therapeutics Development
- AmpliPhi Biosciences Corporation
- F. Hoffmann-La Roche Ltd.
- Knopp Biosciences LLC
- Kyorin Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Co., Inc.
- Oticpharma Ltd
- Paratek Pharmaceuticals, Inc.
- Pfizer Inc.
- Quorum Innovations LLC
- Regeneron Pharmaceuticals Inc
- Therabron Therapeutics, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/bpcznm/sinusitis